Results 111 to 120 of about 2,233 (157)

Effects of Tezepelumab in "United Airway Disease" (Asthma and CRSwNP). [PDF]

Case Rep Pulmonol
Lupia C, Piazzetta GL, Pastore D, Lobello N, Preianò M, Chiarella E, Maglio A, Vatrella A, Pelaia G, Pelaia C.   +9 more
europepmc   +1 more source

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma

International Journal of Molecular Sciences, 2021
Thymic stromal lymphopoietin (TSLP) is an innate cytokine, belonging to the group of alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of cellular and molecular pathways leading to type 2 (T2-high) airway ...
Alessandro Vatrella, Corrado Pelaia, Rosa Terracciano   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Tezepelumab for asthma

Drugs of Today, 2022
The epithelium, once simply considered a protective barrier against harmful agents, has in recent times gained considerable relevance as an entity that can promote and regulate inflammatory processes through the production of cytokines, namely interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP), known as "alarmins".
Nolasco, Santi, Pelaia, Corrado, Scioscia, Giulia, Campisi, Raffaele, Crimi, Claudia   +4 more
openaire   +2 more sources

Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma

Expert Opinion on Investigational Drugs, 2019
Introduction: Thymic stromal lymphopoietin (TSLP) is overexpressed in the airways of severe asthmatics and is an upstream cytokine that orchestrates inflammatory responses in asthma.
Giuseppe Spadaro, Mariantonia Braile, Remo Poto   +2 more
exaly   +2 more sources

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

New England Journal of Medicine, 2021
Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma. The efficacy and safety of tezepelumab in patients with severe, uncontrolled asthma require further assessment.We conducted a phase 3, multicenter, randomized, double-blind, placebo ...
Janet Griffiths, Andrew Menzies-Gow, Arnaud Bourdin   +2 more
exaly   +4 more sources

Short-term therapeutic effectiveness of tezepelumab in patients with severe asthma: A real-world study

International Immunopharmacology
Background: Tezepelumab is a fully human monoclonal antibody which specifically binds to thymic stromal lymphopoietin (TSLP), thus effectively inhibiting its pleiotropic pathogenic actions.
Alessandro Vatrella, Girolamo Pelaia, Enrico Iaccino   +2 more
exaly   +2 more sources

Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis

Cells, 2022
The anti-thymic stromal lymphopoietin antibody (tezepelumab) has therapeutical potential for inadequately controlled asthma. However, evidence comparing tezepelumab with other biologics is scarce.
Koichi Ando, Yosuke Fukuda, Hironori Sagara   +2 more
exaly   +2 more sources